

TRIAL OF MUTE IN GNC ENDS

May 7th 2018. Melbourne, Australia.

Australian nasal and respiratory technology company Rhinomed (ASX:RNO) advises that the trial program of its Mute 'Trial' pack in 811 GNC stores has ended.

The conclusion was that Mute did not fit into GNC's core product range and therefore, Rhinomed will not continue supplying Mute to GNC.

Earnings attributable to GNC stores were not material in Rhinomed's last and current financial years.

Media Enquiries

Michael Johnson, CEO & Director
+61 (03) 8416 0900
mjohnson@rhinomed.global

Follow us on **Twitter** @rhinomedceo and @theturbinecom

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global

About the Mute™

Mute™ is a unique nasal respiratory technology that has been found reduce the volume and frequency of snoring in 75% of users. Mute is easy to use, drug free and fits discreetly inside the nose. Designed to give snoring the silent treatment and made from ultra-soft polymers, Mute gently expands each nostril to increase the volume of air in each breath. By doing so, Mute encourages nasal breathing and reduces the need to open the mouth during sleep, factors critical to a reduction in snoring and better sleep quality. For more information or to purchase online, visit www.mutesnoring.com

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of medical technology products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Rhinomed recommends that investors seek professional advice before making an investment in its shares.